Do CD4+ CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?

Overview

Journal J Immunother

Specialty Allergy & Immunology

Date 2002 May 10

PMID 12000861

Citations 23

Authors

Paul Andrew Antony

Nicholas P Restifo

Affiliations

Soon will be listed here.

Abstract

After years of banishment from mainstream immunology, the notion that one subset of T cells can exert regulatory effects on other T lymphocytes is back in fashion. Recent work in knockout and transgenic mice has begun to bring molecular definition to our understanding of immunoregulatory CD4+CD25+ T cells (Treg/Th3/Tr1). The identification of the glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR, also known as TNFRSF18) expressed on T regulatory cells might afford new therapeutic opportunities. Another possible therapeutic intervention could be the blockade of signaling through the molecular pair of tumor necrosis factor-related activation induced cytokine (TRANCE) and receptor activator of NF-kappaB (RANK). Based on the available evidence from experimental mouse tumor models, however, it seems that simply blocking or even eliminating T regulatory function will not be enough to manage established tumors. The challenge for immunotherapists now is to overcome immunosuppression using the knowledge gained through the understanding of T regulatory cell function.

Citing Articles

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy.

Shen L, Pili R Oncoimmunology. 2012; 1(6):948-950.

PMID: 23162767 PMC: 3489755. DOI: 10.4161/onci.20306.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Shen L, Ciesielski M, Ramakrishnan S, Miles K, Ellis L, Sotomayor P PLoS One. 2012; 7(1):e30815.

PMID: 22303460 PMC: 3267747. DOI: 10.1371/journal.pone.0030815.

From tumor immunosuppression to eradication: targeting homing and activity of immune effector cells to tumors.

Draghiciu O, Nijman H, Daemen T Clin Dev Immunol. 2011; 2011:439053.

PMID: 22190971 PMC: 3235497. DOI: 10.1155/2011/439053.

Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer.

Yang S, Du Y, Wu B, Xu S, Wen J, Zhu M Cancer Immunol Immunother. 2011; 61(3):335-42.

PMID: 21913024 PMC: 11028813. DOI: 10.1007/s00262-011-1108-1.

Tumor-associated macrophages recruit CCR6+ regulatory T cells and promote the development of colorectal cancer via enhancing CCL20 production in mice.

Liu J, Zhang N, Li Q, Zhang W, Ke F, Leng Q PLoS One. 2011; 6(4):e19495.

PMID: 21559338 PMC: 3084880. DOI: 10.1371/journal.pone.0019495.

References

Olivares-Villagomez D, Wang Y, Lafaille J . Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis. J Exp Med. 1998; 188(10):1883-94. PMC: 2212402. DOI: 10.1084/jem.188.10.1883. View

Van de Keere F, Tonegawa S . CD4(+) T cells prevent spontaneous experimental autoimmune encephalomyelitis in anti-myelin basic protein T cell receptor transgenic mice. J Exp Med. 1998; 188(10):1875-82. PMC: 2212404. DOI: 10.1084/jem.188.10.1875. View

Onizuka S, TAWARA I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E . Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 1999; 59(13):3128-33. View

van Elsas A, Hurwitz A, Allison J . Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors.... J Exp Med. 1999; 190(3):355-66. PMC: 2195583. DOI: 10.1084/jem.190.3.355. View

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

Colella T, Bullock T, Russell L, MULLINS D, Overwijk W, Luckey C . Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000; 191(7):1221-32. PMC: 2193167. DOI: 10.1084/jem.191.7.1221. View

Garza K, Agersborg S, Baker E, Tung K . Persistence of physiological self antigen is required for the regulation of self tolerance. J Immunol. 2001; 164(8):3982-9. DOI: 10.4049/jimmunol.164.8.3982. View

Salomon B, Lenschow D, Rhee L, Ashourian N, Singh B, Sharpe A . B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000; 12(4):431-40. DOI: 10.1016/s1074-7613(00)80195-8. View

Shevach E . Regulatory T cells in autoimmmunity*. Annu Rev Immunol. 2000; 18:423-49. DOI: 10.1146/annurev.immunol.18.1.423. View

10.

Read S, Malmstrom V, Powrie F . Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000; 192(2):295-302. PMC: 2193261. DOI: 10.1084/jem.192.2.295. View

11.

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N . Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000; 192(2):303-10. PMC: 2193248. DOI: 10.1084/jem.192.2.303. View

12.

Shevach E . Suppressor T cells: Rebirth, function and homeostasis. Curr Biol. 2000; 10(15):R572-5. DOI: 10.1016/s0960-9822(00)00617-5. View

13.

Jordan M, Boesteanu A, Reed A, Petrone A, Holenbeck A, Lerman M . Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide. Nat Immunol. 2001; 2(4):301-6. DOI: 10.1038/86302. View

14.

DIECKMANN D, Plottner H, Berchtold S, Berger T, Schuler G . Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001; 193(11):1303-10. PMC: 2193384. DOI: 10.1084/jem.193.11.1303. View

15.

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk A . Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med. 2001; 193(11):1285-94. PMC: 2193380. DOI: 10.1084/jem.193.11.1285. View

16.

Rosenberg S . Progress in human tumour immunology and immunotherapy. Nature. 2001; 411(6835):380-4. DOI: 10.1038/35077246. View

17.

Sutmuller R, van Duivenvoorde L, van Elsas A, Schumacher T, Wildenberg M, Allison J . Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001; 194(6):823-32. PMC: 2195955. DOI: 10.1084/jem.194.6.823. View

18.

Pacholczyk R, Kraj P, Ignatowicz L . Peptide specificity of thymic selection of CD4+CD25+ T cells. J Immunol. 2002; 168(2):613-20. DOI: 10.4049/jimmunol.168.2.613. View

19.

Kingsley C, Karim M, Bushell A, Wood K . CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol. 2002; 168(3):1080-6. DOI: 10.4049/jimmunol.168.3.1080. View

20.

NORTH R . Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982; 155(4):1063-74. PMC: 2186638. DOI: 10.1084/jem.155.4.1063. View